Drug therapy to inhibit chemotherapy-induced adverse effects and related pharmaceutical compositions, diagnostics, screening techniques and kits

Abstract

The invention provides a method of treatment comprising reducing therapy-induced adverse effects (TIAE), including chemotherapy-induced adverse effects (CIAE), such as chemotherapy-induced peripheral neuropathy (CIPN) and/or chemotherapy-induced cardiovascular adverse effects (CICAE) in a subject being treated with a CIAE-inducing anti-cancer active ingredient by co-administering to the subject a pharmaceutically effective amount of a NCS-1-protective composition. Related pharmaceutical compositions, diagnostics and screening techniques are also provided.

1 - 61 . (canceled) 
     
     
         62 . A method of treatment comprising inhibiting or preventing the onset of or ameliorating one or more symptoms of cancer therapy-induced adverse effects (CIAE) in a subject being treated with a CIAE-inducing anti-cancer active ingredient by co-administering to the subject a pharmaceutically effective amount of an active compound selected from the group consisting of ibudilast (AV411), AV1013, a pharmaceutically acceptable salt thereof and mixtures thereof wherein said cancer therapy induced adverse effects include neuropathy, peripheral neuropathy and central nervous system effects of reduced cognition/cognitive impairment and adverse effects caused by myelin degradation. 
     
     
         63 . The method of  claim 62 , wherein the CIAE-inducing anti-cancer active ingredient is selected from the group consisting of a taxane, a vinca alkaloid, a radiation sensitizing agent or a mixture thereof. 
     
     
         64 . The method of  claim 63 , wherein:
 (a) the taxane is selected from the group consisting of paclitaxel (Taxol®), docetaxel (Taxoterel®), IDN 5390, GRN1005 and mixtures thereof;   (b) the vinca alkaloid is selected from the group consisting of vinblastine, vincristine, vindesine, vinorelbine and mixtures thereof; and   (c) the radiation sensitizing agent is selected from the group consisting of nimorazole, metronidazole, misonidazole and mixtures thereof.   
     
     
         65 . The method of  claim 62 , wherein said active compound is co-administered with an effective amount of lithium. 
     
     
         66 . The method of  claim 65  wherein said lithium is lithium chloride or lithium carbonate. 
     
     
         67 . The method of  claim 62 , wherein more than one type of CIAE-inducing anti-cancer active ingredient is co-administered to the subject. 
     
     
         68 . The method of  claim 62  wherein the active compound co-administered to the subject between about one half-hour to about eight hours prior to the administration of the CIAE-inducing anti-cancer active ingredient. 
     
     
         69 . The method of  claim 62 , wherein the CIAE-inducing anti-cancer active ingredient is selected from the group consisting of paclitaxel (Taxol®), docetaxel (Taxoterel®), vincristine, metronidazole and mixtures thereof and the active compound is ibudilast or a mixture of ibudilast and lithium. 
     
     
         70 . The method of  claim 62 , wherein the active compound is administered to the subject between about one to about four hours prior to the administration of the CIAE-inducing anti-cancer active ingredient. 
     
     
         71 . The method of  claim 69 , wherein the active compound is administered to the subject about one hour prior to the administration of the CIAE-inducing anti-cancer active ingredient. 
     
     
         72 . The method of  claim 62  wherein the cancer therapy induced adverse effect (CIAE) is neuropathy, peripheral neuropathy or cognitive impairment. 
     
     
         73 . The method of  claim 64  wherein the cancer therapy induced adverse effect (CIAE) is neuropathy, peripheral neuropathy or cognitive impairment. 
     
     
         74 . The method of  claim 67  wherein the cancer therapy induced adverse effect (CIAE) is neuropathy, peripheral neuropathy or cognitive impairment. 
     
     
         75 . The method of  claim 68  wherein the cancer therapy induced adverse effect (CIAE) is neuropathy, peripheral neuropathy or cognitive impairment. 
     
     
         76 . The method of  claim 62  wherein the active compound is ibudilast. 
     
     
         77 . The method of  claim 63  wherein the active compound is ibudilast. 
     
     
         78 . The method of  claim 64  wherein the active compound is ibudilast. 
     
     
         79 . The method of  claim 68  wherein the active compound is ibudilast. 
     
     
         80 . The method of  claim 69  wherein the active compound is ibudilast. 
     
     
         81 . The method of  claim 70  wherein the active compound is ibudilast.